Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma

Overview

This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.

Full Title of Study: “Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 8, 2024

Interventions

  • Drug: 6MHP
    • 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
  • Drug: NeoAg-mBRAF
    • BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
  • Drug: PolyICLC
    • polyICLC, local adjuvant
  • Drug: CDX-1140
    • CDX-1140, local adjuvant

Arms, Groups and Cohorts

  • Experimental: Arm A
    • 6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 for both arms (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given at the primary site at days 1, 8, 16, 38, 67, and 78 and at the replicate site at day 1. A vaccine that contains all components except for CDX-1140 will be given at the replicate site at days 8 and 16. The vaccine will be given subcutaneously/intradermally.
  • Experimental: Arm B
    • 6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 for both arms (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given at the primary site at days 1, 38, 67, and 78 and at the replicate site at days 1, 8, and 16. A vaccine that contains all components except for CDX-1140 will be given at the primary site at days 8 and 16. The vaccine will be given subcutaneously/intradermally.

Clinical Trial Outcome Measures

Primary Measures

  • Safety of CDX-1140 + melanoma peptide vaccine (6MHP and NeoAg-mBRAF) + PolyICLC
    • Time Frame: 30 days after receiving the last dose of study drug
    • Number of participants with dose-limiting toxicities based on CTCAE v5.0
  • Immunogenicity: Impact of addition of CDX-1140 to a melanoma vaccine on persistence of CD4+ Th1 responses
    • Time Frame: Day 127 and/or Day 176
    • Number of participants with persistent C4+ Th1 responses to the melanoma vaccine at either day 127 or day 176, or both

Secondary Measures

  • Immunogenicity: Impact of CDX-1140 on regulatory T cells
    • Time Frame: Day 8 and Day 22
    • Number of FoxP3+ CD4+ T cells per mm^2 in vaccine site biopsies
  • Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on circulating regulatory T cells
    • Time Frame: Through Day 85
    • Number of participants with circulating Tregs (CD4+ FoxP3+) as a proportion of circulating CD4 T cells
  • Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on frequency of CD4+ Th1 responses to vaccine antigens
    • Time Frame: Through Day 176
    • Number of participants with CD4+ T cell response; maximum increase after vaccination at any time point.
  • Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on CD4+ Th1 memory response to vaccine antigens
    • Time Frame: Day 176
    • Number of participants with CD4+ T cell response to the melanoma peptides

Participating in This Clinical Trial

Main Inclusion Criteria:

1. a. For individuals with primary cutaneous, mucosal, or unknown melanoma, an individual must have stage IB ulcerated, II, III, or IV melanoma at original diagnosis or at restaging after recurrence, and be rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration.

b. For patients with stage II, III, or IV uveal melanoma, patients must be rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration.

2. An individual with small radiologic or clinical findings of an indeterminate nature may still be eligible

3. An individual may have had cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma.

4. An individual must have at least 6-10 nevi at least 4 mm in diameter that are located on truncal or non-acral extremity sites and are accessible for biopsy and observation.

5. Diagnosis of melanoma must be confirmed by cytological or histological examination.

6. Individuals will be required to have radiological studies to rule out radiologically evident melanoma metastasis.

7. Individuals who have had brain metastases will be eligible if all of the following are true:

  • Each brain metastasis must have been completely removed by surgery or each unresected brain metastasis must have been treated with stereotactic radiosurgery.
  • No brain metastasis is > 2 cm in diameter at the time of registration.
  • Any neurologic symptoms attributable to brain metastases have returned to baseline.
  • There is no evidence of new or enlarging brain metastases.

8. The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed ≥ 1 week and ≤ 6 months prior to registration.

9. ECOG performance status of 0 or 1 (Section 13.3).

10. Ability and willingness to give informed consent.

11. Adequate organ function as determined by laboratory parameters.

12. Male or female, age 18 years or older at registration.

13. Individuals must have at least two intact (undissected) axillary and/or inguinal lymph node basins

14. For females and males of reproductive potential: agreement to use adequate contraception during study participation and for an additional 3 months after receiving the last dose of study drug.

Main Exclusion Criteria:

1. Individuals who have received the following medications or treatments at any time within 4 weeks of registration:

  • Chemotherapy
  • Interferon (e.g. Intron-A®)
  • Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥ 1 week and ≤ 6 months prior to registration)
  • Allergy desensitization injections
  • High doses of systemic corticosteroids, with some qualifications and exceptions
  • Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)
  • Interleukins (e.g. Proleukin®)
  • Any investigational medication
  • Targeted therapies specific for mutated BRAF or for MEK

2. Individuals who are currently receiving nitrosoureas or who have received this therapy within 6 weeks of registration.

3. Individuals who are currently receiving a checkpoint molecule blockade therapy, or who have received this therapy within 12 weeks of registration.

4. Individuals with known or suspected allergies to any component of the vaccine.

5. Individuals who have received prior melanoma vaccinations with 6MHP plus the mutated BRAF peptide. However, participants who have received prior vaccinations will be eligible to enroll 12 weeks following their last vaccination if they have recurred during or after administration of the vaccine, and if their vaccines did not include all of the synthetic peptides included in this protocol.

6. Individuals who have previously received CDX-1140 or another CD40 agonistic antibody.

7. Pregnancy. Female individuals of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG) obtained within 2 weeks prior to registration.

8. HIV positivity or evidence of active Hepatitis C virus (testing to be done within 6 months of study entry).

9. Female individuals must not be breastfeeding.

10. Individuals in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol in the opinion of the investigator.

11. Individuals classified according to the New York Heart Association classification as having Class III or IV heart disease (Section 13.4).

12. Individuals must not have had prior autoimmune disorders requiring systemic cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement. Participants with an active autoimmune disorder requiring these therapies are also excluded. Some autoimmune disorders will not be exclusionary:

  • The presence of laboratory evidence of autoimmune disease (e.g. positive ANA titer) without symptoms
  • Clinical evidence of vitiligo
  • Other forms of depigmenting illness
  • Mild arthritis requiring non-steroidal anti-inflammatory drugs (NSAID) medications
  • Resolved childhood asthma/atopy
  • Endocrinopathies on stable hormone replacement therapy

13. Individuals with known addiction to alcohol or drugs who are actively taking those agents, or participants with recent (within 1 year) or ongoing illicit IV drug use.

14. Individuals with current pneumonitis. Individuals must not have had pneumonitis within 30 days of registration. Patients who have had complete resolution of prior pneumonitis will be eligible.

15. Individuals who have received a live vaccine within 30 days of registration.

16. Body weight < 110 pounds (50 kg) at registration

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Craig L Slingluff, Jr
  • Collaborator
    • Celldex Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Craig L Slingluff, Jr, Professor of Surgery; Director, Human Immune Therapy Center – University of Virginia
  • Overall Official(s)
    • Craig Slingluff, Principal Investigator, University of Virginia
  • Overall Contact(s)
    • Rupert Egan, MS, (434) 982-1901, RJE5K@hscmail.mcc.virginia.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.